Health ❯Healthcare ❯Medical Research ❯Cancer Treatment

Breast Cancer

New Triple-Drug Regimen Boosts Survival in PIK3CA-Mutant HR+ HER2- Breast Cancer

INAVO120 final data show the regimen doubled the time before disease progression compared with standard therapy.

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex

Breast Cancer Trial Achieves 100% Survival with Pre-Surgery Olaparib